Economy February 26, 2026

Africa CDC raises alarm over data and pathogen-sharing clauses in U.S. health pacts

Contested provisions prompt withdrawals and pushback as African public health agencies weigh implications of bilateral deals

By Leila Farooq
Africa CDC raises alarm over data and pathogen-sharing clauses in U.S. health pacts

The head of the Africa Centres for Disease Control and Prevention said there are significant concerns about data and pathogen-sharing provisions in recent U.S. bilateral health agreements with African countries. Zimbabwe has withdrawn from negotiations over a $367 million, five-year pact citing privacy and equity worries, and Zambia has pushed back on parts of its agreement. Africa CDC says it will support countries that seek to renegotiate or need help implementing any deals they do sign.

Key Points

  • Africa CDC Director-General Jean Kaseya expressed major concerns about data handling and pathogen-sharing requirements in U.S. bilateral health agreements.
  • Zimbabwe withdrew from negotiations on a $367 million, five-year agreement citing worries about sensitive data and unequal terms; Zambia has reportedly pushed back on parts of its deal.
  • The contested clauses would require prompt sharing of pathogen data with Washington and do not guarantee that resulting drugs or vaccines would go to the countries where pathogens were identified - impacting health and pharmaceutical sectors as well as government aid relationships.

Key developments

Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention, told a virtual press briefing on Thursday that there are "huge concerns regarding data, regarding pathogen sharing" in the bilateral agreements the United States is negotiating with African governments. His remarks underscore growing unease among some African nations and health advocates about conditions tied to U.S. global health funding.

On Wednesday, Zimbabwe abandoned talks over what was described as a $367 million pact covering the next five years, saying the proposal raised concerns about sensitive data and represented an unequal arrangement. Zambia has said it pushed back on at least one clause in its own agreement, according to statements reported in recent days.


Nature of the contested provisions

Critics of the agreements have focused in particular on a pathogen-sharing requirement. Under the terms outlined in the agreements, countries would be required to share promptly with Washington data about pathogens that could lead to epidemics in their territories as a condition of receiving U.S. funding. Observers and global health advocates have objected to that element, and have also noted that the accords do not include guarantees that any drugs or vaccines developed following such data sharing would be supplied to the countries where the pathogens were detected.


Context: how these deals fit into U.S. policy

The bilateral pacts are part of a broader shift in how the U.S. government is delivering billions of dollars in global health assistance, actions attributed to the administration of President Donald Trump. The administration has restructured its approach after dismantling its aid agency last year, cutting funding and contracts worldwide, and stating a preference to put "America First" in its global health strategy. Proponents of the new approach have said it channels funds more directly to recipient countries while requiring co-investment from them.


Africa CDC's stance and support

Kaseya said he initially welcomed the revised U.S. approach because it promised more direct funding flows to African countries coupled with co-investment expectations. He also said he turned down a role as an observer to the U.S. negotiations out of respect for the sovereignty of individual nations.

Nevertheless, Kaseya said Africa CDC has provided assistance to countries that have requested help, and will continue to do so. "I said to all of my countries, you have full support from Africa CDC. Even if you want to re-negotiate ... if you want Africa CDC to be there, we’ll be there," he said, offering support both for renegotiation efforts and for implementation assistance where agreements are signed.


Outlook

The developments highlight tensions between donor conditions and recipient concerns over data governance, equity and access to medical countermeasures. Several African governments appear to be re-examining terms and asserting their positions before finalising agreements with the United States.

Risks

  • Pushback or withdrawals by recipient countries could complicate delivery of U.S. global health funding and slow implementation - affecting government-to-government aid channels and public health program rollout.
  • Requirements to share pathogen data without assurances on access to resulting medical countermeasures could fuel concerns over equity and data sovereignty, which may undermine trust between donor and recipient institutions and influence negotiations - relevant to public health and pharmaceuticals.
  • Ambiguity or perceived imbalance in agreement terms may prompt more countries to seek renegotiation or to decline participation, increasing uncertainty for implementation timelines and funding flows in affected health programs.

More from Economy

RBC Tops Quarterly Profit Estimates as Wealth and Personal Banking Drive Growth Feb 26, 2026 Mexico Moves to Block Paris Sale of 40 Pre-Colombian Objects It Says Belong to the Nation Feb 26, 2026 Goolsbee Predicts Multiple Fed Rate Cuts in 2026 but Urges Restraint Feb 26, 2026 Top U.S. Banking Regulator Open to Lawmakers Reviewing World Liberty Financial Charter Filing Feb 26, 2026 Mortgage Rates Slip Under 6% as Market Volatility, Not Fundamentals, Drive Drop Feb 26, 2026